Latest Thalidomide Stories
By Jones, D Beyond Thalidomide: Birth defects explained. Edited by J. McCredie Pp. 418. Royal Society of Medicine Press Ltd. 2007. ISBN: 13: 978-1-85315-741-7. Pounds 35.
Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial.
Celgene, which discovers, develops and commercializes therapies for the treatment of cancer and inflammatory diseases, has announced that Amrubicin has been granted fast track product designation by the FDA for the treatment of small cell lung cancer after first-line chemotherapy.
By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision.
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection.
By CHRIS MALLETT A Teenage music-lover who has been treated for cancer for nearly six years has taken singing lessons with an international gospel choir, thanks to a children's charity.
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients.
Proteolix has started patient dosing in a Phase Ib clinical trial to evaluate the safety and efficacy of Proteolix's lead anticancer agent, carfilzomib, in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma.
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
New Indication Provides Treatment-Free Interval As an Option Media: International Myeloma Foundation Peggy Frank, 818-735-3591 Logo: http://myeloma.org/ The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE(R) (bortezomib) for injection to a wider range of multiple...